Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of Glucagon-like Peptide-1 Receptor Agonists on Mental Illness: Evidence from a Mendelian Randomization Study

18 Mar 2025

Abstract excerpt

Emerging evidence suggests that glucagon-like peptide-1 receptor (GLP1R) agonists may have potential benefits for mental illnesses. However, their exact effects remain unclear. This study investigated the causal relationship between glucagon-like peptide-1 receptor agonist (GLP1RA) and the risk of 10 common mental illnesses, including attention deficit and hyperactivity disorder, anorexia nervosa, anxiety...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diabetes Treatment and Management
Share to Genetic Associations and Epidemiology
Share to Genetics and Neurodevelopmental Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40141382
DOI: 10.3390/ijms26062741

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of Glucagon-like Peptide-1 Receptor Agonists on Mental Illness: Evidence from a Mendelian Randomization StudyPMID 40141382Read ↗

Exploring glucagon-like peptide-1 receptor agonists as potential disease-modifying agent in psychiatric and neurodevelopmental conditions: evidence from a drug target Mendelian randomizationSemantic proximity Read ↗

Causal association between glucagon-like peptide-1 receptor agonists and mental disorders: insight from genetic and real-world evidence.Semantic proximity Read ↗

Glucagon-like peptide-1 receptor activation and mental health: a drug-target Mendelian randomization studySemantic proximity Read ↗

Genetically proxied glucagon-like peptide-1 receptor perturbation and risk of mood disorders: a Mendelian randomization study.Semantic proximity Read ↗

GLP1R gene expression is associated with metabolic and mental health effects in a phenome-wide drug repurposing and safety analysisSemantic proximity Read ↗

Causal effects of lipid-lowering drug targets on psychiatric disorders: A drug-target Mendelian randomization study.Semantic proximity Read ↗

A comprehensive assessment of the association between common drugs and psychiatric disorders using Mendelian randomization and real-world pharmacovigilance database.Semantic proximity Read ↗

In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicidal Ideation and Substance Use DisorderSemantic proximity Read ↗

A meta-analysis of potential genetic factors associated with antipsychotic-induced weight gain in adults with severe mental illness.Semantic proximity Read ↗

Schizophrenia and cardiometabolic abnormalities: A Mendelian randomization studySemantic proximity Read ↗

A Mendelian randomization study of the effect of mental disorders on cardiovascular diseaseSemantic proximity Read ↗

Appraising the causal relationship between plasma caffeine levels and neuropsychiatric disorders through Mendelian randomization.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.